Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations

Background: Noonan syndrome, cardio-facio-cutaneous syndrome (CFC) and Costello syndrome constitute a group of developmental disorders with an overlapping pattern of congenital anomalies. Each of these conditions can be caused by germline mutations in key components of the highly conserved Ras-MAPK pathway, possibly reflecting a similar pathogenesis underlying the three disorders. Germline mutations in KRAS have recently been identified in a small number of patients with Noonan syndrome and CFC. Methods and results: 260 patients were screened for KRAS mutations by direct sequencing. Overall, we detected KRAS mutations in 12 patients, including three known and eight novel sequence alterations. All mutations are predicted to cause single amino acid substitutions. Remarkably, our cohort of individuals with KRAS mutations showed a high clinical variability, ranging from Noonan syndrome to CFC, and also included two patients who met the clinical criteria of Costello syndrome. Conclusion: Our findings reinforce the picture of a clustered distribution of disease associated KRAS germline alterations. We further defined the phenotypic spectrum associated with KRAS missense mutations and provided the first evidence of clinical differences in patients with KRAS mutations compared with Noonan syndrome affected individuals with heterozygous PTPN11 mutations and CFC patients carrying a BRAF, MEK1 or MEK1 alteration, respectively. We speculate that the observed phenotypic variability may be related, at least in part, to specific genotypes and possibly reflects the central role of K-Ras in a number of different signalling pathways.

[1]  D. Brunoni,et al.  CFC index for the diagnosis of cardiofaciocutaneous syndrome. , 2002, American journal of medical genetics.

[2]  B. Gelb,et al.  Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. , 2006, American journal of human genetics.

[3]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[4]  R. Foà,et al.  Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. , 2006, American journal of human genetics.

[5]  H. Ropers,et al.  Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.

[6]  P. Schultz,et al.  Probing the role of loop 2 in Ras function with unnatural amino acids. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Mariman,et al.  Clinical and molecular studies in a large Dutch family with Noonan syndrome. , 1994, American journal of medical genetics.

[8]  R. Hennekam,et al.  Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.

[9]  Bruce D Gelb,et al.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.

[10]  R. Hennekam Costello syndrome: An overview , 2003, American journal of medical genetics. Part C, Seminars in medical genetics.

[11]  W. Reardon,et al.  Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases , 2005, Journal of Medical Genetics.

[12]  E. Zackai,et al.  HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation , 2006, American journal of medical genetics. Part A.

[13]  Pablo Rodriguez-Viciana,et al.  Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome , 2006, Science.

[14]  Kam Y. J. Zhang,et al.  Germline KRAS mutations cause Noonan syndrome , 2006, Nature Genetics.

[15]  B. Neel,et al.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.

[16]  D. Wieczorek,et al.  Cardio‐facio‐cutaneous (CFC) syndrome — a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome , 1997, Clinical genetics.

[17]  I. Vetter,et al.  The Guanine Nucleotide-Binding Switch in Three Dimensions , 2001, Science.

[18]  J. Opitz,et al.  The cardiofaciocutaneous syndrome , 2006, Journal of Medical Genetics.

[19]  C. Der,et al.  Biological and structural characterization of a Ras transforming mutation at the phenylalanine-156 residue, which is conserved in all members of the Ras superfamily. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Herrmann Ras-effector interactions: after one decade. , 2003, Current opinion in structural biology.

[21]  Bruce D Gelb,et al.  Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. , 2006, Human molecular genetics.

[22]  B. Neel,et al.  Stops along the RAS pathway in human genetic disease , 2006, Nature Medicine.

[23]  H. Ropers,et al.  Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.

[24]  Suk Woo Nam,et al.  BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.

[25]  K. Gripp Tumor predisposition in Costello syndrome , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.

[26]  H. Nagai,et al.  Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer. , 2002, Japanese journal of clinical oncology.

[27]  W. Kress,et al.  Genotype-phenotype correlations in Noonan syndrome. , 2004, The Journal of pediatrics.

[28]  Yukichi Tanaka,et al.  Germline mutations in HRAS proto-oncogene cause Costello syndrome , 2005, Nature Genetics.

[29]  K. Rauen Distinguishing Costello versus cardio‐facio‐cutaneous syndrome: BRAF mutations in patients with a Costello phenotype , 2006, American journal of medical genetics. Part A.

[30]  M. Teitell,et al.  Mutations in Costello Syndrome : Detection of Constitutional Activating Mutations in Codon 12 and 13 and Loss of Wild-Type Allele in Malignancy , 2005 .

[31]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[32]  J. Stone,et al.  Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction , 1993, Molecular and cellular biology.